Skip to main content

Table 2 Differences between treatment modalities as per the 2005 St. Gallen guidelines

From: A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study

Risk Category

Endocrine responsive

Endocrine response uncertain

Endocrine nonresponsive

Low risk

ET or Nil

ET or Nil

Not applicable

Intermediate risk

ET alone, or

CT → ET

CT

CT → ET

(CT + ET)

(CT + ET)

 

High risk

CT → ET

CT → ET

CT

 

(CT + ET)

(CT + ET)

 
  1. Abbreviations: ET, endocrine therapy; Nil, no adjuvant systemic therapy; CT, chemotherapy.